Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Jan;99(1):92-7.
doi: 10.1136/bjophthalmol-2014-305076. Epub 2014 Aug 8.

Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study

Yuichiro Ogura  1 , Hiroko Terasaki  2 , Fumi Gomi  3 , Mitsuko Yuzawa  4 , Tomohiro Iida  5 , Miki Honda  6 , Koichi Nishijo  7 , Olaf Sowade  8 , Tetsushi Komori  7 , Ursula Schmidt-Erfurth  9 , Christian Simader  10 , Victor Chong  11 ; VIEW 2 Investigators
Affiliations
Free PMC article
Randomized Controlled Trial

Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study

Yuichiro Ogura et al. Br J Ophthalmol. 2015 Jan.
Free PMC article

Abstract

Background/aims: To evaluate efficacy and safety of intravitreal aflibercept (IVT-AFL) in Japanese patients with wet age-related macular degeneration (wAMD) from the VIEW 2 trial.

Methods: In this double-masked study, patients were randomised to: 0.5 mg IVT-AFL every 4 weeks (0.5q4); 2 mg IVT-AFL every 4 weeks (2q4); 2 mg IVT-AFL every 8 weeks (2q8) after 3 monthly injections; or 0.5 mg ranibizumab every 4 weeks (Rq4). Main efficacy outcomes included vision maintenance and best-corrected visual acuity (BCVA) at week 52.

Results: At week 52, all Japanese patients in the IVT-AFL groups (n=70) maintained vision, compared with 96% of Japanese patients (n=23/24) treated with ranibizumab. Japanese patients in all treatment groups showed improvement in BCVA after treatment. The Rq4, 2q4 and 2q8 groups experienced similar gains in BCVA from baseline. The 0.5q4 group had higher gains due to an unexpected drop in BCVA between screening and baseline. Central retinal thickness and mean area of choroidal neovascularisation decreased in all treatment groups with similar magnitude. Ocular treatment-emergent adverse events were balanced across treatment groups.

Conclusions: IVT-AFL was effective and well tolerated in Japanese patients. Outcomes in this population were consistent with those in the overall VIEW 2 population.

Trial registration number: NCT00637377.

Keywords: Angiogenesis; Clinical Trial; Macula; Neovascularisation; Retina.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient disposition.
Figure 2
Figure 2
Best-corrected visual acuity (BCVA) results. (A) Mean change from baseline; (B) mean absolute score from screening.
Figure 3
Figure 3
Central retinal thickness (CRT) results: mean change from baseline.
See this image and copyright information in PMC

References

    1. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537–48. - PubMed
    1. Bird AC. The Bowman lecture. Towards an understanding of age-related macular disease. Eye (Lond) 2003;17:457–66. - PubMed
    1. Kawasaki R, Wang JJ, Ji GJ, et al. Prevalence and risk factors for age-related macular degeneration in an adult Japanese population: the Funagata study. Ophthalmology 2008;115:1376–81, 1381. - PubMed
    1. Oshima Y, Ishibashi T, Murata T, et al. Prevalence of age related maculopathy in a representative Japanese population: the Hisayama study. Br J Ophthalmol 2001;85:1153–7. - PMC - PubMed
    1. Maruko I, Iida T, Saito M, et al. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 2007;144:15–22. - PubMed

Publication types

MeSH terms

Substances

Associated data